Sean Grant Sells 99,828 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stock

Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) CFO Sean Grant sold 99,828 shares of the firm's stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $39.61, for a total transaction of $3,954,187.08. Following the completion of the transaction, the chief financial officer now directly owns 66,337 shares in the company, valued at approximately $2,627,608.57. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Vera Therapeutics Stock Up 0.3 %

Shares of NASDAQ:VERA traded up $0.11 during trading on Friday, reaching $37.52. The stock had a trading volume of 936,415 shares, compared to its average volume of 1,256,368. Vera Therapeutics, Inc. has a one year low of $5.95 and a one year high of $50.78. The company has a market capitalization of $1.97 billion, a P/E ratio of -16.38 and a beta of 1.05. The company has a current ratio of 7.71, a quick ratio of 7.71 and a debt-to-equity ratio of 0.49. The firm's 50-day simple moving average is $42.72 and its 200 day simple moving average is $24.02.

Institutional Trading of Vera Therapeutics

A number of institutional investors have recently bought and sold shares of VERA. Tower Research Capital LLC TRC boosted its stake in Vera Therapeutics by 810.4% in the 1st quarter. Tower Research Capital LLC TRC now owns 4,834 shares of the company's stock worth $38,000 after purchasing an additional 4,303 shares in the last quarter. Ameritas Investment Partners Inc. boosted its stake in Vera Therapeutics by 163.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,792 shares of the company's stock worth $45,000 after purchasing an additional 1,731 shares in the last quarter. UBS Group AG acquired a new stake in Vera Therapeutics in the 1st quarter worth approximately $47,000. Royal Bank of Canada boosted its stake in Vera Therapeutics by 94.8% in the 2nd quarter. Royal Bank of Canada now owns 3,339 shares of the company's stock worth $54,000 after purchasing an additional 1,625 shares in the last quarter. Finally, Amalgamated Bank boosted its stake in Vera Therapeutics by 26.0% in the 3rd quarter. Amalgamated Bank now owns 4,189 shares of the company's stock worth $57,000 after purchasing an additional 864 shares in the last quarter. 99.21% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

VERA has been the topic of a number of research reports. Raymond James raised shares of Vera Therapeutics from an "outperform" rating to a "strong-buy" rating and raised their target price for the company from $29.00 to $37.00 in a research report on Friday, January 26th. Cantor Fitzgerald initiated coverage on shares of Vera Therapeutics in a research report on Monday, January 8th. They set an "overweight" rating on the stock. HC Wainwright reissued a "buy" rating and set a $25.00 target price on shares of Vera Therapeutics in a research report on Wednesday, December 27th. Wedbush raised their target price on shares of Vera Therapeutics from $21.00 to $34.00 and gave the company a "neutral" rating in a research report on Thursday, March 21st. Finally, Oppenheimer initiated coverage on shares of Vera Therapeutics in a research report on Thursday, January 25th. They set an "outperform" rating and a $26.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Vera Therapeutics presently has an average rating of "Buy" and a consensus price target of $32.29.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.